Company Profile

AJANTA PHARMA LTD.

NSE : AJANTPHARMBSE : 532331ISIN CODE : INE031B01049Industry : Pharmaceuticals & DrugsHouse : Vimal Agrawal
BSE1940.70-17.9 (-0.91 % )
PREV CLOSE (Rs.) 1958.60
OPEN PRICE (Rs.) 1963.75
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 0.00 (0 )
VOLUME 3284
TODAY'S LOW / HIGH (Rs.)1935.10 1970.00
52 WK LOW / HIGH (Rs.)1330 2047.85
NSE1939.80 -16.4 (-0.84 % )
PREV CLOSE(Rs.) 1956.20
OPEN PRICE (Rs.) 1960.00
BID PRICE (QTY) 0.00 (0 )
OFFER PRICE (QTY) 1939.80 (62 )
VOLUME 28230
TODAY'S LOW / HIGH(Rs.) 1936.00 1973.60
52 WK LOW / HIGH (Rs.)1331 2049

Smart Quotes

1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Trade Value (Rs. in Lacs) 0.00
Dividend Yield(%) 0.49
TTM EPS (Rs.) 78.08
P/E Ratio 24.85
Book Value (Rs.) 320.99
Face Value (Rs.) 2
MCap (Rs. in Mn) 167871.63
Price/Earning (TTM) 21.33
Price/Sales (TTM) 6.17
Price/Book (MRQ) 6.04
PAT Margin (%) 24.85
ROCE (%) 34.00
Incorporation Year : 1979

Management Info :

Mannalal B Agrawal - Chairman Yogesh M Agrawal - Managing Director

Registered Office :

Address : Ajanta House,Charkop ,Kandivali (W),
Mumbai,
Maharashtra-400067

Phone : 91-22-66061000

Registrar's Details : Link Intime India Pvt Ltd.
C 101, 247 Park,LBS Marg,Vikhroli (West),Mumbai
Listing : BSE, NSE, MCX
NEWS More
03Jun06-03-2021$Ajanta Pharma informs about newspaper publication Ajanta Pharma informs about
Ajanta Pharma has informed that it enclosed a copy of notice published in Economic Times (English) & Navshakti (Marathi) newspaper, on 2nd June 2021 inviting attention of concerned shareholders to lodge their claims in respect of unclaimed dividends of the Company for last seven years, failing which its shares would be transferred to Investor Education and Protection Fund ('IEPF') account, in accordance with section 124(6) of the Companies Act, 2013 read with Rules.

The above information is a part of company’s filings submitted to BSE.
Ajanta Pharma has informed that it enclosed a copy of notice pu..
10May05-10-2021$Ajanta Pharma earmarks Rs 250 crore capex for FY22 Ajanta Pharma earmarks Rs 25

Ajanta Pharma has earmarked a capex plan of Rs 250 crore for FY22. The company is likely to use the same towards maintenance and some new expansions for the corporate office and some key expansions in the facility. The company operates eight manufacturing facilities in India and Mauritius, including two plants which have been approved by the US Food and Drug Administration (USFDA).

Earlier, the company had earmarked a capex plan of Rs 150 crore for the 2019-20 fiscal. The company had invested Rs 30 crore in the expansion of the corporate office last year, and this year it is going to be in the range of Rs 60-80 crore.

Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacturing and marketing of quality finished dosages.

Ajanta Pharma has earmarked a capex plan of Rs 250 crore for FY..
05May05-05-2021$ Announcement under Regulation 30 (LODR)-Newspaper Publication Announcement under Regulati
Pursuant to Regulation 47 of the Listing Regulations, please find enclosed copies of financial results of the Company for the quarter and year ended 31st March 2021 published in the following newspapers on 1st May 2021: 1. Mumbai edition of Economic Times and 2. Mumbai edition of Maharashtra Times; This is for your information and record.
Pursuant to Regulation 47 of the Listing Regulations, please fi..
04May05-04-2021$Ajanta Pharma informs about written transcript of earnings call Ajanta Pharma informs about

In furtherance to its communication dated 30th April 2021 on earnings call, pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, Ajanta Pharma has informed that a written transcript of the earnings call was held on 30th April 2021 at 5.30 pm has been uploaded on the Company’s website and can be accessed through the link http://ajantapharma.com/Results.aspx.

The above information is a part of company’s filings submitted to BSE.

In furtherance to its communication dated 30th April 2021 on ea..
30Apr04-30-2021$ Grant Of Options Grant Of Options
This is to inform that the Nomination & Remuneration Committee of the Board has at its meeting held today granted options under Ajanta Pharma Share Based Incentive Plan 2019 as detailed below: 1. Total number of options granted - 3,000 2. Number of shares covered under options - 1 share per option 3. Exercise Period - Three months from vesting date This is for your information and record.
This is to inform that the Nomination & Remuneration Committee..
Financials More
Rs. in Millions
QTR Mar 21 ANNUAL 21
Net Profit1547.86756.4
Gross Profit 2167.5 9020.9
Operating Profit 2484.110204.8
Net Sales 7480.727185.9
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group More
Pfizer (BSE)
 5586.35 (1.67%)
M.Cap ( in Cr)
25556.28
Sanofi India (BSE)
 7734.25 (0.52%)
M.Cap ( in Cr)
17814.19
Medicamen Biotech (BSE)
 555.45 (4.62%)
M.Cap ( in Cr)
671.97
JB Chem & Pharma (BSE)
 1545.85 (1.17%)
M.Cap ( in Cr)
11940.08
Bajaj Healthcare (BSE)
 705.05 (2.08%)
M.Cap ( in Cr)
972.91
Shareholding Pattern More
MUTUAL FUNDS/UTI 9.53 %
NON-INSTITUTION 8.67 %
PROMOTERS 70.34 %
FI/BANKS/INSURANCE 1.35 %
GOVERNMENT 0.76 %
FII 0 %
F & O Quotes